Fig. 2: repNP + repGc vaccination is protective up to 1-year post-vaccination.
Groups of WT C57BL6/J mice vaccinated prime-boost with repNP + repGc were treated with MAR1-5A3 antibody to block the type I IFN response and infected with 100 TCID50 CCHFV strain UG3010 3-, 6-, 9-, and 12-months post-boost vaccination. At each timepoint, mice were a challenged on “day 0” and groups of mice were assessed for control of viral loads and survival on days 5 and to day 14, respectively, relative to CCHFV challenge. Mice (N = 8) were monitored for b weight loss and c survival over the course of infection. On day 5 post-infection, mice (N = 6) were evaluated for control of d viral genome copies via qRT-PCR and e infectious virus via TCID50 in the blood, liver, and spleen. Dashed lines indicate limit of detection. Statistical comparisons were calculated using a one-way ANOVA with Turkey’s multiple comparison test. ns >0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data are shown as mean plus standard deviation.
